Helps diagnose suspected or known acute opioid overdosage. ANDA 205014, held by Mylan Institutional. Naloxone Hydrochloride.
As of Nov 22, 2026, ANDA 205014 (Naloxone Hydrochloride), held by Mylan Institutional, was first approved by FDA on Jun 29, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY: Adjunctive Use in Septic Shock ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Naloxone Hydrochloride0.4MG/ML · injectable;injection | Naloxone Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters